Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with moderate COVID-19, A Randomized, Double-blind Clinical Trial

Document Type : Research article

Authors

1 Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

2 Education Development Center, Mazandaran University of Medical Sciences, Sari, Iran.

3 Department of Translational Medicine, University of Liverpool, UK.

4 Antimicrobial Resistance Research Center, Department of Infectious Diseases, Mazandaran University of Medical Sciences, Sari, Iran.

10.22037/ijpr.2021.115157.15243

Abstract

This was a randomized, double-blind clinical trial to compare the efficacy and safety of Atazanavir/Ritonavir (ATZ/RTV) with Lopinavir/Ritonavir (LPV/RTV) in moderate Coronavirus disease 2019 (COVID-19). Participants were randomly assigned to receive a single dose of hydroxychloroquine (HCQ) plus ATZ/RTV or LPV/RTV for a minimum of 5 to a maximum of 10 days. The primary outcomes were the reduced length of hospital stay and clinical recovery within 10 days from starting the intervention. The rate of intensive care unit (ICU) admission, intubation, and mortality, the lengths of ICU stay and being intubated, recovery within 14 days, and the frequency of adverse reactions was considered as secondary outcomes. Among 132 enrolled patients, 62 cases in each arm were analyzed at the end of the intervention. Fifty-one (82.3%) cases in the ATZ/RTV arm versus 41 (66.1%) in the LPV/RTV arm were discharged within 10 days (P = 0.06). The median number of the intervention days was 6 (IQR: 5-8) in ATZ/RTV arm versus 7 (IQR: 6-9) in LPV/RTV arm (P = 0.01). The rate and length of ICU admission and intubation (P ≥ 0.99), rate of mortality (P = 0.49), and recovery within 14 days (P = 0.09) were not statistically different between groups. The most reported adverse reactions were nausea and vomiting that all cases were in the LPV/RTV arm (P = 0.006). ATZ/RTV is better tolerated in comparison with LPV/RTV; however, it did not show more efficacies than LPV/RTV in clinical outcomes of COVID-19 in this study.
 

Graphical Abstract

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with moderate COVID-19, A Randomized, Double-blind Clinical Trial

Keywords


References
 (1) Masters PS. The molecular biology of
coronaviruses. Adv. Virus Res. (2006) 66: 193-292.
 (2) Cucinotta D and Vanelli M. WHO declares
COVID-19 a pandemic. Acta Biomed. (2020) 91: 
287
Nekoukar Z et al. / IJPR (2021), 20 (4): 278-288
157-60.
 (3) Contini A. Virtual screening of an FDA approved
drugs database on two COVID-19 coronavirus
proteins. Biolog. Med. Chem. (2020) 1: 18-37.
 (4) Dayer MR. Old drugs for newly emerging viral
disease, COVID-19: Bioinformatic Prospective.
ArXiv.org preprint arXiv:200304524. 2020.
 (5) Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu
S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K,
Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang
Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang
J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X,
Xu J, Shang L, Zhang Y, Lianjun Cao L, Guo T,
Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby
PW, Cao B and Chen Wang. Remdesivir in adults
with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial. Lancet
(2020) 395: 1569–78.
 (6) Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang
Y, Chen B, Lu M, Lou Y, Ju L, Zhang J and Wang
X. Favipiravir versus arbidol for COVID-19: a
randomized clinical trial. MedRxiv. (2020) 17: 23-
47.
 (7) Davoudi-Monfared E, Rahmani H, Khalili
H, Hajiabdolbaghi M, Salehi M, Abbasian L,
Kazemzadeh H and Yekaninejad MS. A randomized
clinical trial of the efficacy and safety of interferon
β-1a in treatment of severe COVID-19. Antimicrob.
Agents Chemother. (2020) 64: 20.
 (8) Idelsis EM, Jesus PE, Yaquelin DR, Dania VB,
Monica BR, Lisandra BR, Castro-Ríos J, Cobas
Cervantes L, Pagé-Calvet E, Travieso-Pérez
S, Martinez-Suarez C, Ivan Campa-Legra I,
Fernandez-Masso JR, Camacho-Rodriguez H,
Díaz-Gálvez M, Sin-Mayor A, García-Sánchez
M, Martínez-Martín SM, Alonso-Valdés M,
Hernandez-Bernal F, Nodarse-Cuni H, BelloGarcia D, Beato-Canfuk A, Vizcaino M, GuillenNieto GE, Muzio-Gonzalez VL and Bello-Rivero
I. Effect and safety of combination of interferon
alpha-2b and gamma or interferon alpha-2b
for negativization of SARS-CoV-2 viral RNA.
Preliminary results of a randomized controlled
clinical trial. medRxiv. (2020) 29: 15-24.
 (9) Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G,
Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen
N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C,
Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F,
Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z,
Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X,
Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J,
Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu
X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo
L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang
D and Wang C. A trial of lopinavir–ritonavir in
adults hospitalized with severe Covid-19. N. Engl.
J. Med. (2020) 382: 1787-99.
 (10) Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z,
Anushirvani A, Montazeri M, Hosamirudsai H,
Afhami S, Akbarpour E, Aliannejad R, Radmard
AR, Davarpanah AH, Levi J, Wentzel H, Qavi
A, Garratt A, Simmons B, Hill A and Merat S.
Sofosbuvir and daclatasvir compared with standard
of care in the treatment of patients admitted to
hospital with moderate or severe coronavirus
infection (COVID-19): a randomized controlled
trial. J. Antimicrob. Chemother. (2020) 75: 3379-
85.
 (11) Eslami G, Mousaviasl S, Radmanesh E, Jelvay
S, Bitaraf S and Simmons B. The impact of
sofosbuvir/daclatasvir or ribavirin in patients with
severe COVID-19. J. Antimicrob. Chemother.
(2020) 75: 3366-72.
 (12) Chu C, Cheng V, Hung I, Wong M, Chan KH, Chan
KS, Kao R, Poon L, Wong C, Guan Y, Peiris J,
Yuen K and HKU/UCH SARA Study group. Role
of lopinavir/ritonavir in the treatment of SARS:
initial virological and clinical findings. Thorax
(2004) 59: 252-6.
 (13) Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A
and Doherty M. Systematic review of the efficacy
and safety of antiretroviral drugs against SARS,
MERS or COVID‐19: initial assessment. J. Int.
AIDS Soc. (2020) 23: 25489.
 (14) Zhong H, Wang Y, Zhang ZL, Liu YX, Le KJ, Cui
M, Yu YT, Gu ZC, Gao Y and Li HW. Efficacy and
safety of current therapeutic options for COVID19-lessons to be learnt from SARS and MERS
epidemic: A systematic review and meta-analysis.
Pharm. Res. (2020) 157: 104872.
 (15) Raja A, Lebbos J, Kirkpatrick P. Atazanavir
sulphate. Nat. Rev. Drug Discov. (2003) 2: 857-8.
 (16) Sanne I, Piliero P, Squires K, Thiry A, Schnittman
S and Group A-CT. Results of a phase 2 clinical
trial at 48 weeks (AI424-007): a dose-ranging,
safety, and efficacy comparative trial of atazanavir
at three doses in combination with didanosine and
stavudine in antiretroviral-naive subjects. J. Acquir.
Immune Defic. Syndr. (2003) 32: 18-29.
 (17) Le Tiec C, Barrail A, Goujard C and Taburet AM.
Clinical pharmacokinetics and summary of efficacy
and tolerability of atazanavir. Clin. Pharmacokinet.
(2005) 44:1035-50.
 (18) O’Mara E, Smith J and Olsen S. BMS-232632: a
summary of multiple-dose pharmacokinetic, food
effect, and drug interaction studies in healthy
subjects [abstract 504]. 7th Conference on
Retroviruses and Opportunistic Infections, January 
288
ATZ/RTV vs. LPV/RTV in Moderate COVID-19
30-February 2, 2000, San Francisco.
 (19) O’mara E and Drusano G. A preliminary
pharmacokinetic and pharmacodynamic evaluation
of BMS 232632 in protease inhibitor naive HIV+
population pop. AIDS. J. Infect. Dis. (2001) 183:
1126-9.
 (20) Beck BR, Shin B, Choi Y, Park S and Kang K.
Predicting commercially available antiviral drugs
that may act on the novel coronavirus (SARSCoV-2) through a drug-target interaction deep
learning model. Comput. Struct. Biotechnol. J.
(2020) 18: 784-90.
 (21) Zhang L, Lin D, Sun X, Curth U, Drosten C,
Sauerhering L, Becker S, Rox K and Hingerfeld
R. Crystal structure of SARS-CoV-2 main
protease provides a basis for design of improved
α-ketoamide inhibitors. Science (2020) 368: 409-
12.
 (22) Shahab S, Sheikhi M, Alnajjar R, Al Saud S,
Khancheuski M and Strogova A. DFT investigation
of atazanavir as potential inhibitor for 2019-nCoV
coronavirus M protease. J. Mol. Struct. (2020)
129461.
 (23) Rahmani H, Davoudi-Monfared E, Nourian
A, Nabiee M, Sadeghi S, Khalili H, Abbasian
L, Ghiasvand F, Seifi A, Hasannezhad M,
Ghaderkhani S, Mohammadi M and Yekaninejad
MS. Comparing outcomes of hospitalized
patients with moderate and severe COVID-19
following treatment with hydroxychloroquine plus
atazanavir/ritonavir. DARU J. Pharm. Sci. (2020)
28: 625-34.
 (24) Deeks SG, Hecht FM, Swanson M, Elbeik T,
Loftus R, Cohen P, Grant RM. HIV RNA and CD4
cell count response to protease inhibitor therapy in
an urban AIDS clinic: response to both initial and
salvage therapy. AIDS (1999) 13: 35-43.
 (25) de Sousa Silva JD, da Costa Leite S, da Silva
MTS, Meirelles LMA and Andrade AWL. In-silico
evaluation of the inhibitory effect of antiretrovirals
Atazanavir and Darunavir on the main protease
of SARS-CoV-2: docking studies and molecular
dynamics. Res., Soc. Dev. (2020) 9: 826986562.
 (26) Abhinand CS, Nair AS, Krishnamurthy A,
Oommen OV and Sudhakaran PR. Potential
protease inhibitors and their combinations to block
SARS-CoV-2. J. Biomol. Struct. Dyn. 2020: 1-15.
 (27) Fintelman-Rodrigues N, Sacramento CQ, Lima
CR, da Silva FS, Ferreira AC, Mattos M, Freitas
CS, Soares VC, Dias SSG, Tomerozo JR, Miranda
MD, Matos AR, Bozza FA, Carels N, Alves CR,
Siqueira M and Bozza PT. Atazanavir, alone or
in combination with ritonavir, inhibits SARSCoV-2 replication and proinflammatory cytokine
production. Antimicrob. Agents Chemother. (2020)
64: 820-5.
 (28) Gautam N, Roy U, Balkundi S, Puligujja P, Guo
D, Smith N, Liu XM, Lamberty B, Morsey B, Fox
HS, McMillan J, Gendelman HE and Alnouti Y.
Preclinical pharmacokinetics and tissue distribution
of long-acting nanoformulated antiretroviral
therapy. Antimicrob. Agents Chemother. (2013) 57:
3110-20.
 (29) Huang J, Gautam N, Bathena SPR, Roy U,
McMillan J, Gendelman HE, et al. UPLC–MS/
MS quantification of nanoformulated ritonavir,
indinavir, atazanavir, and efavirenz in mouse
serum and tissues. Journal of Chromatography B.
2011;879 (23):2332-8.
 (30) Stanley TL, Joy T, Hadigan CM, Liebau JG,
Makimura H, Chen CY, Thomas BJ, Weise
SB, Robbins GK and Grinspoon SK. Effects of
Switching from Lopinavir/ritonavir to Atazanavir/
ritonavir on Muscle Glucose Uptake and Visceral
Fat in HIV Infected Patients. AIDS (2009) 23:
1349-57.
 (31) Gibert CL. Treatment Guidelines for the Use of
Antiretroviral Agents in HIV-Infected Adults and
Adolescents: An Update. Fed. Pract. (2016) 33:
31-6.
 (32) Mazaherpour H, Sofian M, Farahani E, Abdi A,
Mazaherpour S, Larijani MS abd Ramezani A.
Higher Rate of Hyperbilirubinemia and Arrythmia
in COVID-19 Cases Receiving Combination
Therapy Atazanavir/ritonavir vs. Lopinavir/
ritonavir. Authorea. (2021).
 (33) Sulkowski MS. Drug-induced liver injury
associated with antiretroviral therapy that includes
HIV-1 protease inhibitors. Clin. Infect. Dis. (2004)
38: 90-7.
 (34) Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W,
Tao Q, Sun Z and Xia L. Correlation of chest CT
and RT-PCR testing in coronavirus disease 2019
(COVID-19) in China: a report of 1014 cases.
Radiology (2020) 296: 36-42.